PharmAkea is actively seeking to sell or out-license its two small molecule programs in fibrosis.  The first program is a Phase 2 ready LOXL2 inhibitor.  The second program is a Phase 1 ready ATX inhibitor

Parties that are interested in learning more about either of these opportunities, please do not hesitate to contact Chris King ( This email address is being protected from spambots. You need JavaScript enabled to view it. or Robert Williamson ( This email address is being protected from spambots. You need JavaScript enabled to view it. ).